EU C 001

Drug Profile

EU C 001

Alternative Names: EU-C-001

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer PresSura Neuro
  • Class Antidepressants; Antiemetics; Anxiolytics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Craniocerebral trauma
  • Preclinical Brain injuries

Most Recent Events

  • 04 Apr 2018 PresSura Neuro plans a phase I trial for Brain injuries (In volunteers) in Australia (IV) in April 2018 (ACTRN12618000482268)
  • 09 Mar 2018 PresSura Neuro plans a phase I trial in Brain injuries (In volunteers) in Australia (ACTRN12618000364279)
  • 06 Apr 2017 EU C 001 is still in preclinical development for Brain injuries in Australia (PresSura Neuro website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top